MXPA00002616A - Combinacion de un inhibidor de la monoamina-oxidasa y un antagonista o agonista parcial de h5-ht1b. - Google Patents

Combinacion de un inhibidor de la monoamina-oxidasa y un antagonista o agonista parcial de h5-ht1b.

Info

Publication number
MXPA00002616A
MXPA00002616A MXPA00002616A MXPA00002616A MXPA00002616A MX PA00002616 A MXPA00002616 A MX PA00002616A MX PA00002616 A MXPA00002616 A MX PA00002616A MX PA00002616 A MXPA00002616 A MX PA00002616A MX PA00002616 A MXPA00002616 A MX PA00002616A
Authority
MX
Mexico
Prior art keywords
methyl
naphthyl
tetrahydro
piperazin
mmol
Prior art date
Application number
MXPA00002616A
Other languages
English (en)
Spanish (es)
Inventor
Stefan Berg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA00002616A publication Critical patent/MXPA00002616A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA00002616A 1997-09-18 1998-09-09 Combinacion de un inhibidor de la monoamina-oxidasa y un antagonista o agonista parcial de h5-ht1b. MXPA00002616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination
PCT/SE1998/001602 WO1999013878A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (1)

Publication Number Publication Date
MXPA00002616A true MXPA00002616A (es) 2002-04-24

Family

ID=20408296

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA00002616A MXPA00002616A (es) 1997-09-18 1998-09-09 Combinacion de un inhibidor de la monoamina-oxidasa y un antagonista o agonista parcial de h5-ht1b.

Country Status (27)

Country Link
US (1) US6159970A (cg-RX-API-DMAC10.html)
EP (1) EP1014986B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001516719A (cg-RX-API-DMAC10.html)
KR (2) KR20010024087A (cg-RX-API-DMAC10.html)
CN (1) CN1278727A (cg-RX-API-DMAC10.html)
AR (1) AR013503A1 (cg-RX-API-DMAC10.html)
AT (1) ATE270889T1 (cg-RX-API-DMAC10.html)
AU (1) AU752719B2 (cg-RX-API-DMAC10.html)
BR (1) BR9812236A (cg-RX-API-DMAC10.html)
CA (1) CA2302204A1 (cg-RX-API-DMAC10.html)
DE (1) DE69825062T2 (cg-RX-API-DMAC10.html)
DK (1) DK1014986T3 (cg-RX-API-DMAC10.html)
EE (1) EE200000146A (cg-RX-API-DMAC10.html)
ES (1) ES2222603T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0100621A2 (cg-RX-API-DMAC10.html)
ID (1) ID25789A (cg-RX-API-DMAC10.html)
IL (1) IL134775A0 (cg-RX-API-DMAC10.html)
IS (1) IS5401A (cg-RX-API-DMAC10.html)
MX (1) MXPA00002616A (cg-RX-API-DMAC10.html)
NO (1) NO20001400L (cg-RX-API-DMAC10.html)
PL (1) PL339368A1 (cg-RX-API-DMAC10.html)
PT (1) PT1014986E (cg-RX-API-DMAC10.html)
SE (1) SE9703376D0 (cg-RX-API-DMAC10.html)
SK (1) SK2832000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200000725T2 (cg-RX-API-DMAC10.html)
WO (1) WO1999013878A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA987804B (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957948A (en) * 1988-05-05 1990-09-18 Interface, Inc. Biocidal protective coating for heat exchanger coils
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CN101448803A (zh) * 2006-03-17 2009-06-03 阿斯利康(瑞典)有限公司 用作5-ht6调节剂的四氢萘
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110179988A (zh) * 2019-07-10 2019-08-30 王大伟 五羟色胺再摄取抑制剂和单胺氧化酶抑制剂联合在制备治疗抑郁症或早泄药物中的应用
IL321485A (en) * 2022-12-14 2025-08-01 Luminous Mind Inc Treatment of psychological symptoms affecting other medical conditions (PFAOMC)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
KR20010024087A (ko) 2001-03-26
PL339368A1 (en) 2000-12-18
DK1014986T3 (da) 2004-10-25
US6159970A (en) 2000-12-12
CA2302204A1 (en) 1999-03-25
IS5401A (is) 2000-03-14
BR9812236A (pt) 2000-07-18
DE69825062D1 (de) 2004-08-19
PT1014986E (pt) 2004-10-29
CN1278727A (zh) 2001-01-03
ES2222603T3 (es) 2005-02-01
ATE270889T1 (de) 2004-07-15
WO1999013878A1 (en) 1999-03-25
EP1014986B1 (en) 2004-07-14
AU9193198A (en) 1999-04-05
NO20001400L (no) 2000-05-05
SE9703376D0 (sv) 1997-09-18
NO20001400D0 (no) 2000-03-17
AU752719B2 (en) 2002-09-26
JP2001516719A (ja) 2001-10-02
SK2832000A3 (en) 2000-09-12
ZA987804B (en) 1999-03-18
EE200000146A (et) 2001-02-15
ID25789A (id) 2000-11-02
AR013503A1 (es) 2000-12-27
TR200000725T2 (tr) 2000-08-21
KR20010024084A (ko) 2001-03-26
DE69825062T2 (de) 2005-08-25
EP1014986A1 (en) 2000-07-05
HUP0100621A2 (hu) 2001-08-28
IL134775A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
US6159971A (en) Combination of a 5-HT reuptake inhibitor and a h5-HT1B anatagonist or partial agonist
EP1014986B1 (en) A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST
US6479497B1 (en) Substituted chroman derivatives
EP1021183B1 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST
MXPA00002612A (en) A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B
MXPA00002623A (en) A combination of a selective 5-ht1a
HK1032739B (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
HK1032740B (en) A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist
CZ2000944A3 (cs) Kombinace inhibitoru monoaminoxidázy a antagonisty nebo parciárního agonisty Ii5-HT1B
CZ2000946A3 (cs) Kombinace inhibitoru vychytávání 5-HT a antagonisty nebo parciárního agonisty h5-HTlB
CZ2000945A3 (cs) Kombinace selektivního antagonisty 5-HT1A a selektivního antagonisty nebo parciárního agonisty h5-HTlB